Events

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 23th March, 2012
Time: Presentation 5pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: To List, or Not To List, That is the Question
Presented by David Blake, co-founder and co-editor of Bioshares.

Listing on the stock exchange is one of the key options for companies wanting financial security. But how to know when an IPO will be successful – and how to get to that point? Guest speaker David Blake, co-founder and co-editor of Bioshares will speak about the imperative for companies to have a well developed capital career plan from their inception if they are to maximise the probability of their success. Such an approach impacts on all aspects of the company; their business strategy, product development and management composition.

During his presentation, David will analyse the pathway to success for two listed Australian companies – Acrux (a drug delivery company that completed a $300M license deal) and Mesoblast (a $2B company based on adult stem cells).

Many of you will be familiar with Bioshares as Australia’s leading biotech stock report, delivering independent investment research to investors on ASX listed biotech, pharmaceutical and healthcare companies. It also organises a highly regarded Biotechnology summit each year designed to inform the investment sector and to encourage investment in the life science industry. Last year Bioshares had support from NZTE to hold this summit in New Zealand (Queenstown), attracting many international investors. The summit will be held in Queenstown again this year.

Please join us to discuss with David the mind set and practices he believes biocompanies need to adopt to maximise financial and investment success.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 24th February, 2012
Time: Presentation 4.30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Commercialisation Strategies for Innovating Firms
Presented by Associate Professor Simon Wakeman.

Associate Professor Simon Wakeman has been in New Zealand for the past two months applying his extensive knowledge of commercialisation in the US (by analysing over 1400 products) to issues for NZ companies. Simon describes his presentation as follows: A major issue for start-up firms is how to access the product development and marketing capabilities necessary to get an innovation to market. The decision whether and when to partner with an established firm not only influences the success of the innovation, but also how much value the innovator captures. However, there is considerable variation even within partnership arrangements. This seminar will outline the different arrangements used by biopharmaceutical firms to commercialize their innovation, focusing specifically on the choice between straight licensing arrangements and co-development arrangements. It will present data from the US biotech industry on what drives firms into one arrangement or the other, and how the choice affects their subsequent commercialization success.

Simon_Wakeman

Simon Wakeman is Associate Professor at the European School of Management and Technology (ESMT) in Berlin, Germany. He holds a PhD from the University of California at Berkeley, and prior to joining ESMT was a Research Fellow at the Center for Law & Biosciences at Stanford Law School. His research examines firm strategy for commercializing innovation, with a particular focus on the role that contractual arrangements and intellectual property rights play in that strategy. At ESMT he teaches courses on Business Strategy and Capturing Value from Innovation in the Full-Time MBA, Executive MBA, and Executive Education programs

You are warmly invited to join us to discuss Simon’s insights on how New Zealand companies can best capture value around innovation.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 9th December 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Phil O’Reilly’s, Chief Executive of BusinessNZ
Title: Celebrating ‘Belgium’ (?!?....)

The last Bioscience Enterprise forum for 2011 is not to be missed. We will be celebrating.

We will be celebrating Phil O’Reilly’s vision of an economically vibrant New Zealand. From his position as Chief Executive of BusinessNZ, Phil’s stimulating presentation will look at what is needed to take the results of NZ's innovative skills into the global market.

We will be celebrating the 5th birthday of the MBioEnt qualification and the success of its ‘bilingual’ graduates in creating a bridge between the worlds of science and business.

We will be celebrating the successful completion of this year’s MBE theses as the 2011 interns now prepare to make their mark in the bioscience ecosystem.

We will be celebrating – and acknowledging – the wonderful support the programme has enjoyed from so many people across the bioindustry.

We will celebrate the end of the formalities with the eagerly anticipated, if somewhat inexpert, sabre champagne.

We would love you to join us to mark this occasion - and to debate how successfully the MBioEnt programme has contributed to Phil O’Reilly’s ‘Belgium’.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext. 89625 or 0274 305 758.


2011 Bioscience Enterprise Showcase

Tuesday 15th November; OGGB, University of Auckland

As many of you know, the University of Auckland’s Bioscience Enterprise programme is directed to people who want to see research realise its full value and impact on society by being successfully commercialised. A key element of this programme is the six month placement of interns with a bioscience company to work on a business-science project that forms the basis of their Master’s thesis. It is intended that these projects are of genuine value to the host company – many are currently hosting their 3rd, 4th, or even 5th intern.

We will be presenting the research undertaken by the 5th year of Bioscience Enterprise Master’s students and introducing you to the 2012 interns. This event is for all members of the bioscience industry who see value in the development of NZ’s bioeconomy with personnel who are ‘bilingual’ in both science and business.

The Showcase will allow you to:-

Hear about the science-business research projects that were important to biocompanies this year.

  • Meet the 2011 Master’s of Bioscience Enterprise graduates
  • Meet the 2012 Master’s of Bioscience Enterprise interns
  • Talk to other companies and organisations who are hosting, or have hosted, an MBioEnt intern and/or employed a MBioEnt graduate, as well as academic and programme supervisors
  • Explore the possibilities of the internship programme for your company
  • Be in at the beginning of the process of finding the best possible match between a company, the project and a 2012 internship student


You are warmly invited to attend all or part of the Showcase. Twelve minute presentations of the 2011 MBioEnt projects will run from 9.30 am to 3.00 pm and the Internship Fair will run from 3.00 to 5.00 pm. Posters of the research will be on display throughout the Showcase. The Showcase will be held in the University of Auckland’s Owen G Glenn Building/ Business School in Grafton Rd, Auckland.

You are also warmly invited to consider what science-business issues or projects could be of interest to your company or organisation in 2012 that could be researched by an MBioEnt student. I have attached a small sample of the more than 85 topics that have been investigated by these students over the past five years.

In a few weeks time I will send out further information. I will be inviting companies to nominate a project or projects, to register to meet prospective students before making a decision and/or to register to have a company stand.

In the meantime please feel very welcome to contact Margot Bethell with any queries.

Margot Bethell
Director Bioscience Enterprise Programme
Institute for Innovation in Biotechnology (IIB)
University of Auckland
email: director@bioscienterprise.ac.nz
phone: 373 7599 ext 89625mobile: +64 274 305 758

www.biotech.co.nz

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 14th October 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Dr Fintan Walton, CEO and founder of PharmaVentures
Title: Pharma Ventured, Pharma Gains

Adapting to the huge changes taking place in pharma and biotech – including deals involving nutrition, orphan drugs, wound care, new technologies and even protection against bioterrorism –  PharmaVentures  continues to be a world leader in shaping deals and alliances in this sector.

We are delighted to welcome Dr Fintan Walton, CEO and founder of PharmaVentures, as the guest speaker at October’s forum.  PharmaVentures has 1000 clients in over 38 countries and has executed over 600 assignments for companies that include the major pharmas and biotechs from Baxter and Boehringer Ingleheim to J&J and Merck to Pfizer, Roche and Sanofi.

PharmaVentures assists corporations, investors and legal practices in all aspects of deal transactions, from strategy formulations to execution. It provides specialist strategic advice, transactional services and vital information to empower business decision makers. PharmaVentures also offers expert M&A and out-licensing services with staff experienced in both the life sciences and investment banking industries.

Fintan will examine the current global pharma environment and the impact this is having on the types of deals that are taking place.

Please join us to discuss with Fintan how the changing global trends in the pharma industry are of significance to New Zealand.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz  or phone (09) 373 7599 ext 89625 or 0274 305 758.



An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 16th September 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: David Fisher from Brandon Capital Partners (a Sydney based VC firm that have invested widely in the bioindustry)
Title: And it’s Aussie vs Kiwi....or maybe it’s more Aussie and Kiwi vs the Commercialisation Challenge.

Dr David Fisher, from the Sydney and Melbourne based firm Brandon Capital Partners, will be the guest speaker at the next Bioscience Enterprise forum. Brandon Capital Partners runs the Medical Research Commercialisation Fund, a very similar set up to the Trans Tasman Commercialisation Fund.

Like the TTCF, the MRCF has $30 million for ‘risk tolerant investment’ and, like the TTCF, is a mix of private and government funding. Both funds exclusively support research opportunities from their member organisations with up to $200,000 for research as early as proof-of-concept and a greater amount for supporting the formation of a company (up to $2 million with the MRCF).

The MRCF is a slightly more mature fund, starting in 2007. With the expectation of attracting approximately 10 members, the MRCF now has 27 member organisations.

David’s presentation will look at what has worked for the MRCF and what hasn’t; how they manage the assessment process; what makes a successful bid for funding; how they manage ‘co-opetition’ (where it is to all members’ advantage for the fund to succeed, also advantageous to collaborate to develop a commercial product, yet the funding is limited and, by definition, competitive); how they have worked with –and encouraged – co-investment.

The UofA has access to similar funding through the TTCF, but in co-opetition with four Australian Universities. Questions remain – would this funding model work for NZ Inc?; would NZ organisations support such a model?; is this model the best one for success for NZ companies?

Please join us to hear about David’s experience with the Medical Research Commercialisation Fund – and to contribute to the question. Do we want this for NZ too?

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.


An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 19th August 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Sir Graeme Douglas – founder, owner and Director of Douglas Pharmaceuticals
Title: The Generic Guru

The Douglas Pharmaceutical story is one of adaptability, independence, adaptability, business strategy, and adaptability ... and loyal relationships...and excellent technical skills.

It is with great pleasure that we welcome Sir Graeme Douglas – founder, owner and Director of Douglas Pharmaceuticals – as the guest speaker for the next Bioscience Enterprise forum.

According to Sir Graeme, many people vastly underestimate what is involved in the production of generic medicines. He is referring to the necessary combination of planning, technical skill and financial resources. Add to that understanding Douglas Pharmaceuticals’ sought-after specialisation in the production of high containment, high potency and sometimes toxic drugs and you get some insight to this company’s success.

Set up in 1967 as an importer and distributer of pharmaceuticals, Douglas Pharmaceuticals now has an annual turnover of $150 million, derives 60% of its income from exports, employs 460 personnel – and is debt free. This impressive status is due in no small way to Sir Graeme’s response to challenge.

When NZ law restricted pharmacists to only one shop, Graeme set up his own import and distribution company. Introduction of huge tax penalties on imported goods? – Sir Graeme set up his own manufacturing plant (and an association with Sir Ray Avery for quality control). NZ law prevents even the development of drugs pre-patent expiry? - develop an R&D unit off-shore. Pharmac policy leads to huge loss of contracts? – expand the export market – a lot!

Please join us to gain further insight to this inspiring story direct from ‘the horse’s mouth’.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE (15 July 2011)

Date: Friday 15th July 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speakers: Professor Lyall Hanton, Head of the Dept. of Chemistry, University of Otago and Hamish Findlay, Commercial Manager, OIL
Title: Winning by a Nose

In the race to commercial success an Otago University Team is looking like a winner.

Driven by the challenge for ENT surgeons dealing with post-operative bleeding and scarring, the U of O chemistry team came up with a unique solution – one that has captured the attention of the US based medical technologies company Medtronic – a company with 38,000 employees, a presence in over 120 companies and a revenue of US$16 billion in 2010/11.

The natural biomedical gel the Otago team developed is based on the polymer chitosan derived from crab shells and squid and then combined with starch. The excellent anti-adhesion and haemostatic properties shown in clinical trials, conducted with the University of Adelaide and Wellington company Squidgel, attracted Medtronic despite the early stage of its development.

Partnering with the University of Adelaide and working with Otago Innovation Ltd, the gel has now been licensed to Medtronic for use in ENT applications. The gel also has potential benefits in many other applications such as in neurosurgery, abdominal and gynaecological surgery. The ongoing research and rights surrounding these applications remains with the research team.

You are warmly invited to hear more about the science behind this gel from Professor Lyall Hanton, Head of the Dept. of Chemistry, University of Otago, and more about the business deal from Hamish Findlay, Commercial Manager, OIL.

Please join us to gain an insight to this exciting early stage deal between a multi-billion $, multinational company and the highly effective ‘down-under’ team of clinicians, chemists and commercialisation specialists.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE (17 June 2011)

Date: Friday 17th June 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Hon. Dr. Wayne Mapp, Minister for Science and Innovation
Title: Mapping A Global Ambition

At this month’s Bioscience Enterprise Forum MTANZ and the Hon. Dr. Wayne Mapp, Minister for Science and Innovation, will launch the medical technology sector’s blueprint – A Global Ambition. This exciting document is the result of a comprehensive survey of all areas of the medical technology industry. The sector blueprint:

  • Investigates the role of the medical technology manufacturers in New Zealand's economy
  • Highlights global trends in the medical device market
  • Discusses key figures regarding the New Zealand-based manufacturers
  • Investigates key initiatives for growth of this sector in the past two years


Offers recommendations for growth of this sector Highlights include:-

MTANZ_4squares

Please join us for an evening of stimulating discussion and networking. All welcome. Please RSVP to Margot Bethell at director@bioscienterprise.ac.nz.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE (13 May 2011)

Date: Friday 13th May 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Peter Landon-Lane, CEO of Plant & Food Research
Title: CRIs – Where to now?

The Bioscience Enterprise programme and the IIB are delighted to welcome Peter Landon-Lane, CEO of Plant & Food Research as the guest speaker at our next Friday Forum.

Peter Landon-Lane took up the role of Chief Executive Officer at the Plant & Food Research in September 2008 with a background in international business in the food and agri-industries. He had a number of senior positions in the Fonterra and the New Zealand Dairy Board, including heading the businesses in Japan (1998-2004) and Europe (2005-2008) after starting his career at the former Department of Trade and Industry, serving as a trade commissioner in China and the Philippines.

Peter has degrees in science from the University of Otago and in economics from Victoria University of Wellington. He is currently a board director of several Plant & Food Research subsidiaries, joint ventures and research collaborations, including Prevar Limited, Seafood Innovations Limited, the Vital Vegetables Research Partnership and the Riddet Institute.

On this occasion Peter will discuss the new operating environment for CRIs and what it means for research collaborations, for industry and government clients and for employment opportunities.

Peter will also briefly discuss Plant & Food’s interests and activities in two key areas, food and bioactives.

Please join us for this interesting and informative insight into CRIs in general and Plant and Food Research in particular.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758

Public car parking is available nearby under the U of A’s Business School, the Owen G Glenn Building, in Grafton Rd. (see attached map). There is also limited parking available in Princes St.

Margot Bethell
Director Bioscience Enterprise Programme
Institute for Innovation in Biotechnology (IIB)
University of Auckland
email: director@bioscienterprise.ac.nz
phone: 373 7599 ext 89625
mobile: +64 274 305 758